Nilotinib Viatris

Nilotinib, the active ingredient in Nilotinib Viatris, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It targets BCR‑ABL positive cells and is used in the treatment of chronic myeloid leukemia in adult patients, including all disease phases. The medication is formulated for systemic absorption and is indicated for patients with Philadelphia chromosome‑positive chronic myeloid leukemia across disease phases.

GNH USA supplies Nilotinib Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics to support clinical programs across global markets.

Nilotinib is indicated for chronic myeloid leukemia, a BCR‑ABL driven hematologic malignancy.

- Chronic myeloid leukemia (chronic phase): provides disease control and prolongs survival. - Chronic myeloid leukemia (accelerated phase): helps achieve hematologic and cytogenetic response. - Chronic myeloid leukemia (blast phase): offers targeted inhibition of leukemic proliferation.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Rash: mild skin irritation. - Nausea: occasional upset stomach. - Diarrhea: loose stools. - Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects: - Cardiovascular events: including arterial occlusion. - Severe hepatotoxicity: marked liver injury. - Pancreatitis: inflammation of the pancreas.

When prescribing Nilotinib, clinicians should consider several safety precautions.

- Monitor cardiac function: assess for ischemic events and hypertension. - Check liver enzymes: perform baseline and periodic hepatic function tests. - Assess pancreatic enzymes: monitor amylase and lipase levels. - Evaluate for QT prolongation: obtain ECG and correct electrolyte imbalances. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Nilotinib interacts with several medicines that can alter its exposure or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers: such as rifampin, reduce nilotinib levels. - Antacids containing aluminum or magnesium: decrease absorption if taken simultaneously. - Concomitant use with QT‑prolonging drugs: may increase risk of arrhythmia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors: like fluconazole, can raise nilotinib concentrations. - Warfarin: may require INR monitoring due to potential interaction.